<DOC>
	<DOC>NCT01784770</DOC>
	<brief_summary>To collect retrospectively the efficacy and safety information of azithromycin IV on patients with Legionnaires' disease related to their appropriate use in daily practice.</brief_summary>
	<brief_title>Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Legionnaires' Disease</mesh_term>
	<mesh_term>Legionellosis</mesh_term>
	<criteria>All patients who are prescribed Azithromycin (Zithromac) IV for Legionnaires' disease. Patients who have been prescribed Zithromac or Zithromac SR.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Legionnaires' disease</keyword>
	<keyword>Legionella pneumophila</keyword>
	<keyword>Zithromax</keyword>
	<keyword>Zithromac</keyword>
	<keyword>Japanese</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>